Kliewer, K. L., Murray-Petzold, C., Collins, M. H., Abonia, J. P., Bolton, S. M., DiTommaso, L. A., … Rothenberg, M. E. (2023). Benralizumab for eosinophilic gastritis: a single-site, randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet Gastroenterology & Hepatology, 8(9), 803–815. https://doi.org/10.1016/s2468-1253(23)00145-0

Kliewer, Kara L., Cristin Murray-Petzold, Margaret H. Collins, Juan P. Abonia, Scott M. Bolton, Lauren A. DiTommaso, Lisa J. Martin, et al. “Benralizumab for eosinophilic gastritis: a single-site, randomised, double-blind, placebo-controlled, phase 2 trial.” The Lancet Gastroenterology & Hepatology 8, no. 9 (September 2023): 803–15. https://doi.org/10.1016/s2468-1253(23)00145-0.

Kliewer KL, Murray-Petzold C, Collins MH, Abonia JP, Bolton SM, DiTommaso LA, et al. Benralizumab for eosinophilic gastritis: a single-site, randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet Gastroenterology & Hepatology. 2023 Sep;8(9):803–15.

Kliewer, Kara L., et al. “Benralizumab for eosinophilic gastritis: a single-site, randomised, double-blind, placebo-controlled, phase 2 trial.” The Lancet Gastroenterology & Hepatology, vol. 8, no. 9, Elsevier BV, Sept. 2023, pp. 803–15. Crossref, doi:10.1016/s2468-1253(23)00145-0.

Kliewer KL, Murray-Petzold C, Collins MH, Abonia JP, Bolton SM, DiTommaso LA, Martin LJ, Zhang X, Mukkada VA, Putnam PE, Kellner ES, Devonshire AL, Schwartz JT, Kunnathur VA, Rosenberg CE, Lyles JL, Shoda T, Klion AD, Rothenberg ME. Benralizumab for eosinophilic gastritis: a single-site, randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet Gastroenterology & Hepatology. Elsevier BV; 2023 Sep;8(9):803–815.